To determine whether the administration of small amounts of glucose through an oral spray device (GSD) facilitates weight loss in overweight/obese subjects involved in a lifestyle modification programme. We randomly assigned 56 overweight/obese subjects to either the treatment group (n = 32) or the control group (n = 24). All subjects in both groups followed a structured dietary programme of 6,280.2 kJ (1,500 kcal)/day and exercised minimum 150 min a week and were followed-up for a period of 60 days. Subjects assigned to the treatment group were asked to spray, during early symptoms of neuroglycopenia, 10 puffs by GSD. GSD is a device that delivers to the buccal mucosa 50 mg of glucose per puff. A mean weight loss of 3.5 ± 3.0 kg in GSD-treated group compared to 1.7 ± 2.1 kg in control group (p = 0.01) was observed. Significant differences regarding reduction of BMI (-1.3 ± 1.0 vs. -0.7 ± 0.8 kg/m2; p = 0.01) and waist circumference (-3.5 ± 3.2 vs. -0.9 ± 3.5 cm; p = 0.02) were also detected. A short-term use of GSD, in association with dietary restriction and exercise, is helpful in improving weight loss and in reducing waist circumference in overweight/obese subjects.

New technologies aiding dietary programmes for weight control: the oral glucose spray / Khazrai, Yeganeh Manon; Maddaloni, Ernesto; Altomare, Maria; Cacciapaglia, Fabio; Pozzilli, Paolo. - In: ENDOCRINE. - ISSN 1355-008X. - 45:2(2014), pp. 288-292. [10.1007/s12020-013-9987-x]

New technologies aiding dietary programmes for weight control: the oral glucose spray

Maddaloni, Ernesto;Pozzilli, Paolo
2014

Abstract

To determine whether the administration of small amounts of glucose through an oral spray device (GSD) facilitates weight loss in overweight/obese subjects involved in a lifestyle modification programme. We randomly assigned 56 overweight/obese subjects to either the treatment group (n = 32) or the control group (n = 24). All subjects in both groups followed a structured dietary programme of 6,280.2 kJ (1,500 kcal)/day and exercised minimum 150 min a week and were followed-up for a period of 60 days. Subjects assigned to the treatment group were asked to spray, during early symptoms of neuroglycopenia, 10 puffs by GSD. GSD is a device that delivers to the buccal mucosa 50 mg of glucose per puff. A mean weight loss of 3.5 ± 3.0 kg in GSD-treated group compared to 1.7 ± 2.1 kg in control group (p = 0.01) was observed. Significant differences regarding reduction of BMI (-1.3 ± 1.0 vs. -0.7 ± 0.8 kg/m2; p = 0.01) and waist circumference (-3.5 ± 3.2 vs. -0.9 ± 3.5 cm; p = 0.02) were also detected. A short-term use of GSD, in association with dietary restriction and exercise, is helpful in improving weight loss and in reducing waist circumference in overweight/obese subjects.
2014
Administration, Oral; Adult; Body Mass Index; Body Weight; Exercise; Female; Follow-Up Studies; Glucose; Humans; Life Style; Male; Middle Aged; Obesity; Overweight; Treatment Outcome; Waist Circumference; Weight Reduction Programs; Diet, Reducing; Oral Sprays
01 Pubblicazione su rivista::01a Articolo in rivista
New technologies aiding dietary programmes for weight control: the oral glucose spray / Khazrai, Yeganeh Manon; Maddaloni, Ernesto; Altomare, Maria; Cacciapaglia, Fabio; Pozzilli, Paolo. - In: ENDOCRINE. - ISSN 1355-008X. - 45:2(2014), pp. 288-292. [10.1007/s12020-013-9987-x]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1276318
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact